Chronische und akute Herzinsuffizienz – Neue Erkenntnisse und Studien des letzten Jahres

Schlüsselwörter

ESC-Richtlinien - akutes Herzversagen - chronisches Herzversagen - erhaltene linksventrikuläre Ejektionsfraktion - pharmakologische Behandlung

Keywords

ESC guidelines - acute heart failure - chronic heart failure - preserved left ventricular ejection fraction - pharmacological treatment

• Literatur

• 1 Anand IS, Assmann SF, Boineau R et al. Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). NCT00094302 American Heart Association Scientific Sessions 2013; Late Breaking Trial Session, 18.11.2013
• 2 Anker SD, Comin Colet J, Filippatos G et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436-2448
• 3 Böhm M, Borer J, Ford I et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013; 102: 11-22
• 4 Böhm M, Swedberg K, Komajda M et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010; 376: 886-894
• 5 Boos CJ, Nam M, Camm AJ. Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure. Heart Fail Rev 2014; 19: 391-401
• 6 Borer JS, Böhm M, Ford I et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). Am J Cardiol 2014; 113: 497-503
• 7 Chatterjee S, Moeller C, Shah N et al. Eplerenone is not superior to older and less expensive aldosterone antagonists. Am J Med 2012; 125: 817-825
• 8 Collier TJ, Pocock SJ, McMurray JJ et al. The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. Eur Heart J 2013; 34: 2823-2829
• 9 Edelmann F, Wachter R, Schmidt AG et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013; 309: 781-791
• 10 Filippatos G, Farmakis D, Colet JC et al. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. Eur J Heart Fail 2013; 15: 1267-1276
• 11 Fox K, Komajda M, Ford I et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. Eur Heart J 2013; 34: 2263-2270
• 12 Franke J, Wolter JS, Meme L et al. Optimization of pharmacotherapy in chronic heart failure: is heart rate adequately addressed?. Clin Res Cardiol 2013; 102: 23-31
• 13 Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta 2012; 1823: 1434-1443
• 14 Gheorghiade M, Bohm M, Greene SJ et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 2013; 309: 1125-1135
• 15 Greene SJ, Vaduganathan M, Wilcox JE et al. The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. JACC Heart Fail 2013; 1: 488-496
• 16 Groenveld HF, Januzzi JL, Damman K et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008; 52: 818-827
• 17 Homma S, Thompson JL, Pullicino PM et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012; 366: 1859-1869
• 18 Homma S, Thompson JL, Sanford AR et al. Benefit of warfarin compared with aspirin in patients with heart failure in sinus rhythm: a subgroup analysis of WARCEF, a randomized controlled trial. Circ Heart Fail 2013; 6: 988-997
• 19 Krum H, Shi H, Pitt B et al. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study. Circ Heart Fail 2013; 6: 711-718
• 20 Lip GY, Ponikowski P, Andreotti F et al. Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Eur J Heart Fail 2012; 14: 681-695
• 21 Maggioni AP, Greene SJ, Fonarow GC et al. Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. Eur Heart J 2013; 34: 3117-3127
• 22 McAlister FA, Wiebe N, Ezekowitz JA et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009; 150: 784-794
• 23 McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-1847
• 24 Neuberger HR, Mewis C, van Veldhuisen DJ et al. Management of atrial fibrillation in patients with heart failure. Eur Heart J 2007; 28: 2568-2577
• 25 Philipson H, Ekman I, Forslund HB et al. Salt and fluid restriction is effective in patients with chronic heart failure. Eur J Heart Fail 2013; 15: 1304-1310
• 26 Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717
• 27 Redfield MM, Chen HH, Borlaug BA et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013; 309: 1268-1277
• 28 Rienstra M, Damman K, Mulder BA et al. Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. JACC Heart Fail 2013; 1: 21-28
• 29 Savard LA, Thompson DR, Clark AM. A meta-review of evidence on heart failure disease management programs: the challenges of describing and synthesizing evidence on complex interventions. Trials 2011; 12: 194
• 30 Schowalter M, Gelbrich G, Stork S et al. Generic and disease-specific health-related quality of life in patients with chronic systolic heart failure: impact of depression. Clin Res Cardiol 2013; 102: 269-278
• 31 Shah SJ, Heitner JF, Sweitzer NK et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2013; 6: 184-192
• 32 Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-885
• 33 Swedberg K, Young JB, Anand IS et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013; 368: 1210-1219
• 34 Takimoto E, Champion HC, Li M et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005; 11: 214-222
• 35 Tavazzi L, Swedberg K, Komajda M et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. Eur J Heart Fail 2013; 15: 1296-1303
• 36 Tebbe U, Tschope C, Wirtz JH et al. Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HF. Clin Res Cardiol 2014; 103: 665-673
• 37 Zannad F, McMurray JJ, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21